IECM
NVO

Intrinsic Edge Capital Management’s Novo Nordisk NVO Stock Holding History

Intrinsic Edge Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$1.59M – 199
2023
Q1 		$1.59M Sell
20,000
-40,000
-67% -$2.84M 0.16% 119
2022
Q4 		$4.06M Buy
+60,000
New +$3.52M 0.4% 94

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Intrinsic Edge Capital Management's NVO Position: Q2 2023 in Review

Intrinsic Edge Capital Management sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 20,000 shares — an estimated $1.59M sold.

Intrinsic Edge Capital Management first reported a position in NVO in Q4 2022 and held it in 2 quarters. The position peaked at $4.06M in Q4 2022. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

  • Intrinsic Edge Capital Management reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 20,000 Novo Nordisk shares in Q2 2023, an estimated $1.59M.
  • Intrinsic Edge Capital Management first reported a position in Novo Nordisk in Q4 2022 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Novo Nordisk position peaked at $4.06M in Q4 2022.
  • 1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Intrinsic Edge Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.